| Literature DB >> 34863618 |
Julia H Rogers1, Sarah N Cox2, James P Hughes3, Amy C Link4, Eric J Chow4, Idabelle Fosse5, Margaret Lukoff5, M Mia Shim6, Timothy M Uyeki7, Constance Ogokeh7, Michael L Jackson8, Michael Boeckh9, Janet A Englund10, Emily Mosites7, Melissa A Rolfes7, Helen Y Chu4.
Abstract
INTRODUCTION: Little is known about COVID-19 vaccination intent among people experiencing homelessness. This study assesses surveyed COVID-19 vaccination intent among adult homeless shelter residents and staff and identifies factors associated with vaccine deliberation (responded "undecided") and reluctance (responded "no"), including time trends.Entities:
Keywords: COVID-19; Health inequities; Homeless; SARS-CoV-2; Shelter; Vaccination
Mesh:
Substances:
Year: 2021 PMID: 34863618 PMCID: PMC8590934 DOI: 10.1016/j.vaccine.2021.11.026
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641
Events of interest related to COVID-19 vaccine confidence in Washington State.
| Event Description | Date Implemented | |
|---|---|---|
| 1 | Institution of Washington (WA) statewide restrictions on openings and public gatherings | 16 November 2020 |
| 2 | Emergency Use Authorization for the BNT162b2 mRNA (Pfizer) COVID-19 vaccine by the U.S. Food and Drug Administration | 11 December 2020 |
| 3 | Initiation of Phase 1A Tier 1 COVID-19 vaccination in WA High-risk workers in health care settings High-risk first responders Long-term care facility residents | 14 December 2020 |
| 4 | Initiation of Phase 1B Tier 1 COVID-19 vaccination in WA, extending eligibility to: All people 65 years and older People 50 years and older living in multigenerational households Workers in childcare settings Pre-K-12 educators and school staff | 18 January 2021 |
| 5 | First discovery of the SARS-CoV-2 variant B.1.1.7 in WA | 23 January 2021 |
COVID-19 Vaccine Response Team, Meehan K, Hanewall B. COVID-19 Vaccine Prioritization Guidance and Allocation Framework.; 2021. https://www.doh.wa.gov/Portals/1/Documents/1600/coronavirus/820–112-VaccineAllocationPrioritization.pdf.
Last survey responses for COVID-19 vaccine uptake, when it becomes available, from unique participants.*
| Intent to Be Vaccinated, | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resident | Staff | |||||||||||
| No | Yes | Undecided | Received vaccine | Total | P-value | No | Yes | Undecided | Received | Total | P-value | |
| 36.0 [18.0, 80.0] | 45.0 [18.0, 85.0] | 38.0 [18.0, 72.0] | 48.5 [41.0, 51.0] | <0.001 | 38.5 [20.0, 68.0] | 29.0 [18.0, 78.0] | 40.0 [21.0, 71.0] | 31.0 [21.0, 81.0] | 0.004 | |||
| 18–49 y | 142 (31.8%) | 212 (47.4%) | 90 (20.1) | 3 (0.7%) | 0.001 | 35 (14.5%) | 139 (57.7%) | 37 (15.4%) | 30 (12.4%) | 0.33 | ||
| 50–64 y | 35 (20%) | 118 (67.4%) | 21 (12%) | 1 (0.6%) | 6 (13.3%) | 23 (51.1%) | 11 (24.4%) | 5 (11.1%) | ||||
| ≥65 y | 12 (24%) | 31 (62%) | 7 (14%) | 0 (0%) | 1 (9.1%) | 5 (45.5%) | 1 (9.1%) | 4 (36.4%) | ||||
| American Indian/ Alaska Native | 9 (34.6%) | 11 (42.3%) | 5 (19.2%) | 1 (3.8%) | 0.001 | 1 (25.0%) | 1 (25.0%) | 2 (50.0%) | 0 (0.0%) | <0.001 | ||
| Asian | 2 (11.1%) | 15 (83.3%) | 1 (5.6%) | 0 (0.0%) | 3 (10.3%) | 19 (65.5%) | 3 (10.3%) | 4 (13.8%) | ||||
| Black/African American | 75 (34.7%) | 100 (46.3%) | 39 (18.1%) | 2 (0.9%) | 29 (39.7%) | 16 (21.9%) | 20 (27.4%) | 8 (11.0%) | ||||
| Multiple | 21 (44.7%) | 19 (40.4%) | 7 (14.9%) | 0 (0.0%) | 0 (0.0%) | 11 (64.7%) | 2 (11.8%) | 4 (23.5%) | ||||
| Native Hawaiian/ Pacific Islander | 14 (37.8%) | 17 (45.9%) | 6 (16.2%) | 0 (0.0%) | 0 (0.0%) | 2 (28.6%) | 4 (57.1%) | 1 (14.3%) | ||||
| White | 46 (19.7%) | 145 (62.0%) | 43 (18.4%) | 0 (0.0%) | 7 (4.7%) | 108 (73.0%) | 11 (7.4%) | 22 (14.9%) | ||||
| 19 (19.0%) | 61 (61.0%) | 20 (20.0%) | 0 (0%) | 0.12 | 1 (3.4%) | 17 (58.6%) | 8 (27.6%) | 3 (10.3%) | 0.13 | |||
| 113 (27.4%) | 244 (59.2%) | 54 (13.1%) | 1 (0.2%) | <0.001 | 10 (9.4%) | 70 (66.0%) | 13 (12.3%) | 13 (12.3%) | 0.06 | |||
| ≤6 months | 60 (32.8%) | 87 (47.5%) | 35 (19.1%) | 1 (0.5%) | 0.24 | NA | NA | NA | NA | NA | ||
| 7–12 months | 34 (35.8%) | 46 (48.4%) | 15 (15.8%) | 0 (0.0%) | NA | NA | NA | NA | ||||
| 13–24 months | 20 (27.4%) | 42 (57.5%) | 10 (13.7%) | 1 (1.4%) | NA | NA | NA | NA | ||||
| ≥24 months | 68 (23.7%) | 171 (59.6%) | 46 (16.0%) | 2 (0.7%) | NA | NA | NA | NA | ||||
| Less than high school | 42 (30.0%) | 75 (53.6%) | 23 (16.4%) | 0 (0.0%) | 0.02 | 1 (12.5%) | 4 (50.0%) | 3 (37.5%) | 0 (0.0%) | <0.001 | ||
| High school / GED | 74 (27.4%) | 139 (51.5%) | 55 (20.4%) | 2 (0.7%) | 18 (30.0%) | 25 (41.7%) | 14 (23.3%) | 3 (5.0%) | ||||
| Some college | 55 (28.1%) | 112 (57.1%) | 29 (14.8%) | 0 (0.0%) | 14 (19.7%) | 33 (46.5%) | 20 (28.2%) | 4 (5.6%) | ||||
| Bachelors or higher | 9 (20.9%) | 28 (65.1%) | 4 (9.3%) | 2 (4.7%) | 9 (5.7%) | 105 (66.9%) | 11 (7.0%) | 32 (20.4%) | ||||
| 35 (32.1%) | 51 (46.8%) | 23 (21.1%) | 0 (0.0%) | 0.30 | 41 (14.7%) | 150 (54.0%) | 49 (17.6%) | 38 (13.7%) | 0.02 | |||
| 148 (26.9%) | 305 (55.4%) | 95 (17.2%) | 3 (0.5%) | 0.20 | 40 (14.3%) | 157 (56.1%) | 45 (16.1%) | 38 (13.6%) | 0.99 | |||
| 40 (20.6%) | 111 (57.2%) | 40 (20.6%) | 3 (1.5%) | 0.01 | 7 (11.1%) | 38 (60.3%) | 12 (19.0%) | 6 (9.5%) | 0.64 | |||
| 2.00 [1.00, 31.0] | 2.00 [1.00, 27.0] | 2.00 [1.00, 25.0] | 12.0 [3.00, 16.0] | 0.05 | 1.50 [1.00, 15.0] | 2.00 [1.00, 15.0] | 2.00 [1.00, 20.0] | 6.00 [1.00, 16.0] | <0.001 | |||
| 13 (19.7%) | 40 (60.6%) | 12 (18.2%) | 1 (1.5%) | 0.25 | 3 (21.4%) | 6 (42.9%) | 1 (7.1%) | 4 (28.6%) | 0.20 | |||
| Concerns about vaccine safety | 60 (72.3%) | NA | 23 (27.7%) | NA | <0.001 | 14 (38.9%) | NA | 22 (61.1%) | NA | 0.005 | ||
| Need more information | 21 (28.8%) | NA | 52 (71.2%) | NA | 6 (26.1%) | NA | 17 (73.9%) | NA | ||||
| Not worried about COVID-19 | 8 (72.7%) | NA | 3 (27.3%) | NA | 1 (50.0%) | NA | 1 (50.0%) | NA | ||||
| Not enough time | 1 (50.0%) | NA | 1 (50.0%) | NA | 0 (0.0%) | NA | 0 (0.0%) | NA | ||||
| Already had COVID-19 | 3 (100.0%) | NA | 0 (0.0%) | NA | 1 (100.0%) | NA | 0 (0.0%) | NA | ||||
| Want to prioritize high-risk persons | 1 (100.0%) | NA | 0 (0.0%) | NA | 1 (33.3%) | NA | 2 (66.7%) | NA | ||||
| Unlisted reason | 81 (74.3%) | NA | 28 (25.7%) | NA | 18 (72.0%) | NA | 7 (28.0%) | NA | ||||
| 56 (19.2%) | 196 (67.4%) | 37 (12.7%) | 2 (0.7%) | <0.001 | 9 (5.4%) | 107 (63.7%) | 20 (11.9%) | 32 (19.0%) | <0.001 | |||
| Concerns about vaccine safety | 32 (51.6%) | 18 (29.0%) | 12 (19.4%) | 0 (0.0%) | <0.001 | 4 (50.0%) | 1 (12.5%) | 2 (25.0%) | 1 (12.5%) | 0.02 | ||
| Not worried about flu | 10 (35.7%) | 8 (28.6%) | 10 (35.7%) | 0 (0.0%) | 8 (50.0%) | 3 (18.8%) | 4 (25.0%) | 1 (6.2%) | ||||
| I plan to get the flu vaccine | 6 (12.8%) | 26 (55.3%) | 15 (31.9%) | 0 (0.0%) | 2 (6.9%) | 21 (72.4%) | 4 (13.8%) | 2 (6.9%) | ||||
| Other reason | 72 (39.6%) | 83 (45.6%) | 26 (14.3%) | 1 (0.5%) | 16 (26.2%) | 27 (44.3%) | 15 (24.6%) | 3 (4.9%) |
| |||
Excludes participants that responded “Prefer not to say” when asked about vaccination intent.
All columns apart from “Total” have calculated row percentages; “Total” column percentages calculated exclude missing responses.
Underlying conditions include asthma, blood disorders, cancer, chronic obstructive pulmonary disease or emphysema, immunosuppression, liver disease, heart disease, diabetes, neurologic conditions or aspirin therapy.
Aggregated responses: “Do not have the time to get vaccinated” (n = 29); “Not required for work or school” (n = 2); “Not recommended by a doctor or healthcare worker” (n = 2); “Not covered by health insurance” (n = 3); “Not offered at a convenient location” (n = 12); “None of the above” (n = 195).
Fig. 1bProportion of survey responses citing primary reason for COVID-19 vaccine deliberation or reluctance, by CDC Epidemiological Week (N = 1476)*. (*Overlaid key events are detailed in Supplemental Table 1 in chronological order; Does not include responses from those already vaccinated (n = 75) or those that answered “yes” (n = 2293); Overall proportion of responses that were included as “Other reason”: “Do not have time to get vaccinated” (0.3%); “Want to make sure high-risk individuals get it first” (1.2%); “I’ve already had COVID-19 and don’t think I need the vaccine” (2.3%); “None of the above” (27.2%).)
Fig. 1aProportion of survey responses for COVID-19 vaccine uptake when it becomes available, by Centers for Disease Control & Prevention (CDC) Epidemiological Week (N = 3966)*. (*Overlaid key events are detailed in Supplemental Table 1 in chronological order.)
Fig. 1cProportion of survey responses for seasonal flu vaccine uptake, by CDC Epidemiological Week (N = 3889)*. (*Does not include responses from those that answered “Prefer not to say” when asked about seasonal influenza vaccine status (n = 77).)
Fig. 1dProportion of survey responses citing primary reason for not receiving seasonal flu vaccine, by CDC Epidemiological Week (N = 1768)*. (*Does not include responses from those already vaccinated against seasonal flu (n = 1977) or those that answered “prefer not to say” (n = 144), Overall proportion of responses that were included as “Other reason”: “Do not have the time to get vaccinated” (4.2%); “Not required for work or school” (0.4%); “Not recommended by a doctor or healthcare worker” (0.2%); “Not covered by health insurance” (0.4%); “Not offered at a convenient location” (2.9%); “None of the above” (40%).)
Fig. 2Sankey diagrams of COVID-19 vaccination intent vacillation, based on first and last survey response (N = 589).
Multinomial logistic model predicting intent to receive COVID-19 vaccine at last survey response based on first response (N = 587).*
| Last Survey (ref = vaccine accepting) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Vaccine deliberative | Vaccine reluctant | Received at least one vaccine dose | |||||||
| First Survey (ref. = vaccine accepting) | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value |
| Vaccine deliberative | 11.34 | 6.41–20.05 | 5.96 | 3.22–11.04 | 1.25 | 0.52–3.01 | 0.622 | ||
| Vaccine reluctant | 9.43 | 4.66–19.08 | 30.75 | 16.70–56.62 | NA | NA | NA | ||
Excludes participants vaccinated at first response.
aOR = adjusted odds ratio.
Multivariate predictors of vaccine deliberation or vaccine reluctance regarding intent to be vaccinated, according to multinomial model, based on last survey response (N = 752).*
| Vaccine deliberative (“undecided” vs. “yes/received”) | Vaccine reluctant (“no” vs. “yes/received”) | |||||
|---|---|---|---|---|---|---|
| Characteristic | aOR | 95% CI | P-value | aOR | 95% CI | P-value |
| 18–49 y | 1.03 | 0.41–2.62 | 0.947 | 1.75 | 0.72–4.24 | 0.215 |
| 50–64 y | 0.72 | 0.26–1.94 | 0.511 | 0.90 | 0.34–2.33 | 0.824 |
| ≥ 65 y | Reference | Reference | ||||
| American Indian/ Alaska Native | 1.98 | 0.61–6.49 | 0.257 | 3.20 | 1.13–9.02 | 0.028 |
| Asian | 0.34 | 0.08–1.52 | 0.157 | 0.63 | 0.20–1.94 | 0.418 |
| Black/African American | 1.69 | 1.02–2.78 | 0.040 | 2.47 | 1.57–3.88 | <0.001 |
| Multiple | 0.94 | 0.36–2.41 | 0.892 | 2.41 | 1.17–4.96 | 0.017 |
| Native Hawaiian/ Pacific Islander | 1.01 | 0.35–2.88 | 0.987 | 1.32 | 0.54–3.25 | 0.540 |
| White | Reference | Reference | ||||
| Hispanic or Latino | 1.29 | 0.59–2.82 | 0.524 | 0.50 | 0.21–1.20 | 0.120 |
| Non-Hispanic or Latino | Reference | Reference | ||||
| Female | 2.26 | 1.42–3.60 | 0.001 | 1.45 | 0.96–2.17 | 0.076 |
| Male | Reference | Reference | ||||
| Resident | 1.41 | 0.68–2.91 | 0.358 | 1.96 | 1.00–3.83 | 0.048 |
| Staff | Reference | Reference | ||||
| Less than high school | 3.90 | 1.46–10.36 | 0.006 | 3.51 | 1.54–8.03 | 0.003 |
| High school / GED | 4.69 | 2.06–10.69 | <0.001 | 3.34 | 1.63–6.86 | 0.001 |
| Some college | 4.56 | 2.03–10.27 | <0.001 | 3.38 | 1.66–6.90 | 0.001 |
| Bachelors or higher | Reference | Reference | ||||
| Yes | 1.43 | 0.76–2.68 | 0.269 | 1.11 | 0.63–1.93 | 0.723 |
| No | Reference | Reference | ||||
| Yes | 1.36 | 0.84–2.21 | 0.211 | 0.77 | 0.48–1.23 | 0.268 |
| No | Reference | Reference | ||||
| 2 | 0.79 | 0.40–1.56 | 0.496 | 0.54 | 0.29–0.99 | 0.045 |
| 3–5 | 1.02 | 0.57–1.83 | 0.949 | 1.05 | 0.64–1.71 | 0.846 |
| ≥6 | 1.23 | 0.69–2.18 | 0.488 | 0.76 | 0.45–1.28 | 0.304 |
| 1 | Reference | Reference | ||||
| Yes | 0.63 | 0.29–1.36 | 0.242 | 0.50 | 0.25–1.00 | 0.049 |
| No | Reference | Reference | ||||
| Yes | 0.43 | 0.27–0.67 | <0.001 | 0.36 | 0.24–0.53 | <0.001 |
| No | Reference | Reference | ||||
Based on complete case responses (N = 752); responses “yes” or “received vaccine” combined is the reference group for the outcome.
aOR = adjusted odds ratio.
Underlying conditions include asthma, blood disorders, cancer, chronic obstructive pulmonary disease or emphysema, immunosuppression, liver disease, heart disease, diabetes, neurologic conditions or aspirin therapy.